Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pramipexole vs Bromocriptine for Non-motor Symptoms in Early PD
NCT01673724Phase 4Completed
- Sponsor
- Sandoz
- Start
- Feb 2012
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pramipexole in Parkinson's disease (PD) (2 arms), sponsored by Sandoz. Primary endpoint: Korean Non-Motor Symptoms Scale at 24 weeks. Started Feb 2012; status: completed.
02
Drugs
pramipexole
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT01673724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01673724.